Sign up to save your podcasts
Or
Share Pfizer's 2025 Outlook: Navigating Uncertain Terrain with Financial Projections and Analyst Forecasts
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Pfizer's 2025 Outlook: Navigating Uncertain Terrain with Financial Projections and Analyst Forecasts
As of April 28, 2025, Pfizer's stock price is around $22.92, according to the latest market data. This is a slight increase from the day's open of $22.77 and the intraday low of $22.48, with the intraday high reaching $23.11[2]. The trading volume for Pfizer stock on April 25, 2025, was 30.362 million shares, which is lower than the TTM average trading volume of 13.329 million shares[1].
Pfizer has recently provided its full-year 2025 guidance, anticipating revenues to be in the range of $61.0 to $64.0 billion, including expectations for revenue from various products. The company also reaffirmed its full-year 2024 guidance and provided detailed financial projections, including a diluted EPS guidance range of $2.80 to $3.00, with an expected operational growth of 10% to 18% from the midpoint of 2024 guidance after adjusting for non-recurring items in 2024[4].
In terms of cost savings, Pfizer aims to achieve an additional $500 million in savings in 2025 from its ongoing cost realignment program, on top of the $4.0 billion in net cost savings achieved through 2024. The first phase of the manufacturing optimization program is on track to deliver initial net cost savings in the latter part of 2025, aiming to improve gross margin performance[4].
Major analysts have provided various forecasts for Pfizer's stock price in 2025. WalletInvestor predicts a slight decline, with a forecast range of $23.837 to $28.105, while PandaForecast anticipates sustained growth, with a predicted range of $26.46 to $40.15 by the end of the year[5]. These forecasts indicate high volatility in the stock's performance, reflecting both potential declines and significant growth.
Overall, Pfizer's stock performance is influenced by its strong financial guidance, ongoing cost-saving initiatives, and varying analyst forecasts. The current stock price and trading volume suggest a stable market presence, but the future trajectory remains uncertain and subject to various market and economic factors.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
Pfizer has recently provided its full-year 2025 guidance, anticipating revenues to be in the range of $61.0 to $64.0 billion, including expectations for revenue from various products. The company also reaffirmed its full-year 2024 guidance and provided detailed financial projections, including a diluted EPS guidance range of $2.80 to $3.00, with an expected operational growth of 10% to 18% from the midpoint of 2024 guidance after adjusting for non-recurring items in 2024[4].
In terms of cost savings, Pfizer aims to achieve an additional $500 million in savings in 2025 from its ongoing cost realignment program, on top of the $4.0 billion in net cost savings achieved through 2024. The first phase of the manufacturing optimization program is on track to deliver initial net cost savings in the latter part of 2025, aiming to improve gross margin performance[4].
Major analysts have provided various forecasts for Pfizer's stock price in 2025. WalletInvestor predicts a slight decline, with a forecast range of $23.837 to $28.105, while PandaForecast anticipates sustained growth, with a predicted range of $26.46 to $40.15 by the end of the year[5]. These forecasts indicate high volatility in the stock's performance, reflecting both potential declines and significant growth.
Overall, Pfizer's stock performance is influenced by its strong financial guidance, ongoing cost-saving initiatives, and varying analyst forecasts. The current stock price and trading volume suggest a stable market presence, but the future trajectory remains uncertain and subject to various market and economic factors.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
View all episodes
By Inception Point AiAs of April 28, 2025, Pfizer's stock price is around $22.92, according to the latest market data. This is a slight increase from the day's open of $22.77 and the intraday low of $22.48, with the intraday high reaching $23.11[2]. The trading volume for Pfizer stock on April 25, 2025, was 30.362 million shares, which is lower than the TTM average trading volume of 13.329 million shares[1].
Pfizer has recently provided its full-year 2025 guidance, anticipating revenues to be in the range of $61.0 to $64.0 billion, including expectations for revenue from various products. The company also reaffirmed its full-year 2024 guidance and provided detailed financial projections, including a diluted EPS guidance range of $2.80 to $3.00, with an expected operational growth of 10% to 18% from the midpoint of 2024 guidance after adjusting for non-recurring items in 2024[4].
In terms of cost savings, Pfizer aims to achieve an additional $500 million in savings in 2025 from its ongoing cost realignment program, on top of the $4.0 billion in net cost savings achieved through 2024. The first phase of the manufacturing optimization program is on track to deliver initial net cost savings in the latter part of 2025, aiming to improve gross margin performance[4].
Major analysts have provided various forecasts for Pfizer's stock price in 2025. WalletInvestor predicts a slight decline, with a forecast range of $23.837 to $28.105, while PandaForecast anticipates sustained growth, with a predicted range of $26.46 to $40.15 by the end of the year[5]. These forecasts indicate high volatility in the stock's performance, reflecting both potential declines and significant growth.
Overall, Pfizer's stock performance is influenced by its strong financial guidance, ongoing cost-saving initiatives, and varying analyst forecasts. The current stock price and trading volume suggest a stable market presence, but the future trajectory remains uncertain and subject to various market and economic factors.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
Pfizer has recently provided its full-year 2025 guidance, anticipating revenues to be in the range of $61.0 to $64.0 billion, including expectations for revenue from various products. The company also reaffirmed its full-year 2024 guidance and provided detailed financial projections, including a diluted EPS guidance range of $2.80 to $3.00, with an expected operational growth of 10% to 18% from the midpoint of 2024 guidance after adjusting for non-recurring items in 2024[4].
In terms of cost savings, Pfizer aims to achieve an additional $500 million in savings in 2025 from its ongoing cost realignment program, on top of the $4.0 billion in net cost savings achieved through 2024. The first phase of the manufacturing optimization program is on track to deliver initial net cost savings in the latter part of 2025, aiming to improve gross margin performance[4].
Major analysts have provided various forecasts for Pfizer's stock price in 2025. WalletInvestor predicts a slight decline, with a forecast range of $23.837 to $28.105, while PandaForecast anticipates sustained growth, with a predicted range of $26.46 to $40.15 by the end of the year[5]. These forecasts indicate high volatility in the stock's performance, reflecting both potential declines and significant growth.
Overall, Pfizer's stock performance is influenced by its strong financial guidance, ongoing cost-saving initiatives, and varying analyst forecasts. The current stock price and trading volume suggest a stable market presence, but the future trajectory remains uncertain and subject to various market and economic factors.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI